Nifty
:
25571.25
Sensex
:
82814.71
116.90 (0.46%)
316.57 (0.38%)
Nifty
Sensex
:
:
25571.25
82814.71
116.90 (0.46%)
316.57 (0.38%)

Dr. Reddy's Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 500124 | NSE: DRREDDY

NSE BSE
1280.40
20-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1281.9
  •  1292.4
  •  1275
  •  1282.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1753200
  •  2249053135.3
  •  1379.7
  •  1020

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,06,859.35
  • 19.19
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,09,308.55
  • 0.62%
  • 2.87

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.64%
  • 0.31%
  • 7.65%
  • FII
  • DII
  • Others
  • 22.34%
  • 27.92%
  • 15.14%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.69
  • 11.38
  • 9.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.08
  • 17.17
  • 6.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.37
  • 23.71
  • 7.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.47
  • 20.21
  • 19.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.65
  • 3.68
  • 3.43

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.35
  • 13.91
  • 11.65

Earnings Forecasts:

(Updated: 14-02-2026)
Description
2024
2025
2026
2027
Adj EPS
67.89
61.54
56.05
65.57
P/E Ratio
18.86
20.81
22.84
19.53
Revenue
32553.5
34422.4
35553.5
38933.1
EBITDA
8547.1
7771.85
7548.82
8517.75
Net Income
5655.1
5023.02
4592.8
5345.79
ROA
12.83
10.05
8.34
9.17
P/B Ratio
3.17
2.83
2.63
2.39
ROE
18.36
14.4
11.78
12.42
FCFF
1881.3
3534.68
3953
4097.72
FCFF Yield
1.79
3.36
3.75
3.89
Net Debt
-1120.4
-4351.8
-7487.84
-9501.2
BVPS
403.46
453.01
486.82
536.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
8,753.40
8,381.20
4.44%
8,828.30
8,038.20
9.83%
8,572.10
7,696.10
11.38%
8,528.40
7,113.80
19.89%
Expenses
6,865.90
6,108.20
12.40%
6,818.40
5,961.70
14.37%
6,398.50
5,566.20
14.95%
6,530.50
5,282.60
23.62%
EBITDA
1,887.50
2,273.00
-16.96%
2,009.90
2,076.50
-3.21%
2,173.60
2,129.90
2.05%
1,997.90
1,831.20
9.10%
EBIDTM
21.56%
27.12%
22.77%
25.83%
25.36%
27.68%
23.43%
25.74%
Other Income
268.80
150.20
78.96%
323.90
307.50
5.33%
290.30
187.20
55.07%
522.10
197.50
164.35%
Interest
94.40
81.70
15.54%
90.70
75.70
19.82%
83.00
59.80
38.80%
65.60
59.30
10.62%
Depreciation
521.00
471.40
10.52%
504.60
397.00
27.10%
476.10
380.60
25.09%
454.70
367.70
23.66%
PBT
1,540.90
1,870.10
-17.60%
1,738.50
1,911.30
-9.04%
1,904.80
1,876.70
1.50%
1,999.70
1,601.70
24.85%
Tax
353.60
470.10
-24.78%
408.00
575.50
-29.11%
495.10
490.20
1.00%
418.50
295.40
41.67%
PAT
1,187.30
1,400.00
-15.19%
1,330.50
1,335.80
-0.40%
1,409.70
1,386.50
1.67%
1,581.20
1,306.30
21.04%
PATM
13.56%
16.70%
15.07%
16.62%
16.45%
18.02%
18.54%
18.36%
EPS
14.49
16.95
-14.51%
16.13
15.06
7.10%
16.98
16.70
1.68%
19.10
15.71
21.58%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
34,682.20
32,643.90
28,011.10
24,669.70
21,545.20
19,047.50
17,517.00
15,448.20
14,281.00
14,196.10
15,568.30
Net Sales Growth
11.06%
16.54%
13.54%
14.50%
13.11%
8.74%
13.39%
8.17%
0.60%
-8.81%
 
Cost Of Goods Sold
11,876.50
9,979.90
8,208.70
7,657.70
7,442.20
6,078.90
5,554.40
4,494.80
4,039.50
3,696.50
3,758.50
Gross Profit
22,805.70
22,664.00
19,802.40
17,012.00
14,103.00
12,968.60
11,962.60
10,953.40
10,241.50
10,499.60
11,809.80
GP Margin
65.76%
69.43%
70.69%
68.96%
65.46%
68.09%
68.29%
70.90%
71.71%
73.96%
75.86%
Total Expenditure
26,613.30
24,096.80
20,078.00
18,320.70
17,777.80
15,177.60
15,046.60
12,270.00
11,929.80
11,723.90
11,983.00
Power & Fuel Cost
-
562.50
533.90
477.40
390.50
320.50
314.80
329.10
329.30
330.10
315.20
% Of Sales
-
1.72%
1.91%
1.94%
1.81%
1.68%
1.80%
2.13%
2.31%
2.33%
2.02%
Employee Cost
-
5,580.00
5,030.10
4,646.60
3,885.80
3,629.90
3,380.20
3,356.20
3,214.90
3,106.80
3,117.40
% Of Sales
-
17.09%
17.96%
18.84%
18.04%
19.06%
19.30%
21.73%
22.51%
21.88%
20.02%
Manufacturing Exp.
-
2,563.20
2,087.20
1,738.60
1,602.20
1,574.40
1,445.40
1,434.80
1,746.50
1,886.60
1,856.40
% Of Sales
-
7.85%
7.45%
7.05%
7.44%
8.27%
8.25%
9.29%
12.23%
13.29%
11.92%
General & Admin Exp.
-
2,016.60
1,848.20
1,497.50
1,547.60
1,251.80
1,195.20
1,132.10
1,193.40
1,339.90
1,271.40
% Of Sales
-
6.18%
6.60%
6.07%
7.18%
6.57%
6.82%
7.33%
8.36%
9.44%
8.17%
Selling & Distn. Exp.
-
3,082.10
2,248.20
1,989.40
1,919.20
1,567.70
1,408.30
1,423.50
1,330.20
1,293.40
1,181.10
% Of Sales
-
9.44%
8.03%
8.06%
8.91%
8.23%
8.04%
9.21%
9.31%
9.11%
7.59%
Miscellaneous Exp.
-
312.50
121.70
313.50
990.30
754.40
1,748.30
99.50
76.00
70.60
1,181.10
% Of Sales
-
0.96%
0.43%
1.27%
4.60%
3.96%
9.98%
0.64%
0.53%
0.50%
3.10%
EBITDA
8,068.90
8,547.10
7,933.10
6,349.00
3,767.40
3,869.90
2,470.40
3,178.20
2,351.20
2,472.20
3,585.30
EBITDA Margin
23.27%
26.18%
28.32%
25.74%
17.49%
20.32%
14.10%
20.57%
16.46%
17.41%
23.03%
Other Income
1,405.10
1,097.30
894.30
1,055.50
484.70
291.40
620.60
337.50
155.20
171.50
295.00
Interest
333.70
282.90
171.10
142.80
95.80
97.00
98.30
88.90
78.80
63.40
82.60
Depreciation
1,956.40
1,703.70
1,470.00
1,250.20
1,165.20
1,228.80
1,163.10
1,134.80
1,077.20
1,026.60
938.90
PBT
7,183.90
7,657.80
7,186.30
6,011.50
2,991.10
2,835.50
1,829.60
2,292.00
1,350.40
1,553.70
2,858.80
Tax
1,675.20
1,954.30
1,623.10
1,541.20
878.90
931.90
-140.30
385.80
438.00
296.50
751.10
Tax Rate
23.32%
25.52%
22.59%
25.64%
29.38%
32.87%
-7.67%
16.83%
32.43%
19.08%
26.27%
PAT
5,508.70
5,655.10
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
2,107.70
PAT before Minority Interest
5,554.10
5,725.20
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
2,107.70
Minority Interest
45.40
-70.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
15.88%
17.32%
19.91%
18.27%
10.13%
10.25%
11.57%
12.62%
6.39%
8.86%
13.54%
PAT Growth
1.48%
1.38%
23.75%
106.52%
11.83%
-3.67%
3.90%
113.72%
-27.43%
-40.35%
 
EPS
74.05
76.02
74.98
60.59
29.34
26.23
27.23
26.21
12.27
16.90
28.33

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
33,549.60
28,254.80
23,286.10
19,212.40
17,641.70
15,598.80
14,023.60
12,571.60
12,262.10
12,569.80
Share Capital
83.40
83.40
83.30
83.20
83.20
83.10
83.00
83.00
82.90
85.30
Total Reserves
33,321.50
28,040.10
23,057.10
18,985.90
17,431.90
15,411.90
13,861.10
12,406.00
12,098.80
12,393.90
Non-Current Liabilities
632.90
-36.80
-278.30
-508.30
-197.30
-807.50
2,113.00
2,538.40
456.10
876.70
Secured Loans
406.40
219.00
127.80
194.60
249.90
130.40
55.20
63.00
59.70
74.70
Unsecured Loans
380.00
380.00
0.00
380.00
380.00
0.00
2,144.80
2,445.90
485.20
993.80
Long Term Provisions
29.80
23.90
19.90
25.80
50.80
74.50
79.30
81.70
84.20
95.20
Current Liabilities
13,033.80
9,588.00
8,572.10
9,765.80
8,103.80
7,214.10
5,897.30
6,893.80
8,419.90
6,347.10
Trade Payables
2,647.80
2,614.40
2,268.40
2,266.20
1,810.90
1,524.80
1,367.10
1,334.50
1,056.90
906.80
Other Current Liabilities
5,503.10
4,775.20
4,697.90
3,660.60
3,338.10
3,512.00
2,820.70
2,411.40
2,339.70
2,409.10
Short Term Borrowings
3,804.50
1,272.30
739.00
2,708.20
2,314.50
1,653.20
1,212.50
2,556.20
4,362.60
2,271.80
Short Term Provisions
1,078.40
926.10
866.80
1,130.80
640.30
524.10
497.00
591.70
660.70
759.40
Total Liabilities
47,594.10
37,806.00
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60
Net Block
18,226.40
10,425.60
9,219.10
8,121.50
8,205.70
6,850.30
7,191.00
6,968.00
6,930.70
6,563.00
Gross Block
33,145.70
24,527.40
25,567.10
23,096.40
21,886.70
19,335.50
18,048.40
17,436.30
15,932.40
15,019.70
Accumulated Depreciation
14,754.40
14,101.30
16,348.00
14,894.90
13,632.10
12,485.20
10,857.40
10,468.30
9,001.70
8,456.70
Non Current Assets
22,576.00
13,000.70
11,154.50
10,682.00
10,997.90
9,406.30
10,923.80
11,505.40
11,454.40
7,999.60
Capital Work in Progress
2,465.60
1,419.30
1,030.10
1,293.40
1,565.10
1,535.10
2,933.50
3,470.50
3,324.50
772.20
Non Current Investment
720.40
525.50
536.30
593.00
833.30
309.10
334.20
465.30
682.60
329.70
Long Term Loans & Adv.
341.40
541.80
355.90
451.70
377.00
688.70
426.70
564.80
482.10
290.40
Other Non Current Assets
822.20
88.50
13.10
222.40
16.80
23.10
38.40
36.80
34.50
44.30
Current Assets
25,018.10
24,805.30
20,425.40
17,787.90
14,535.20
12,599.10
11,110.10
10,498.40
9,683.70
11,794.00
Current Investments
3,330.60
4,405.00
4,449.50
2,022.90
1,378.50
2,368.70
2,252.90
1,833.00
1,427.10
3,503.40
Inventories
7,108.50
6,355.20
4,867.00
5,088.40
4,541.20
3,506.70
3,357.90
2,908.90
2,852.80
2,557.90
Sundry Debtors
9,042.00
8,029.80
7,248.50
6,676.40
4,964.10
5,027.80
3,986.90
4,052.70
3,798.60
4,125.00
Cash & Bank
2,460.20
1,727.70
1,730.20
2,419.20
2,078.80
205.30
222.80
263.80
386.50
492.10
Other Current Assets
3,076.80
1,011.30
1,203.50
736.90
1,572.60
1,490.60
1,289.60
1,440.00
1,218.70
1,115.60
Short Term Loans & Adv.
2,004.30
3,276.30
926.70
844.10
722.70
444.50
439.80
674.10
767.20
722.50
Net Current Assets
11,984.30
15,217.30
11,853.30
8,022.10
6,431.40
5,385.00
5,212.80
3,604.60
1,263.80
5,446.90
Total Assets
47,594.10
37,806.00
31,579.90
28,469.90
25,533.10
22,005.40
22,033.90
22,003.80
21,138.10
19,793.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
4,642.80
4,543.30
5,887.50
2,810.80
3,570.30
2,984.10
2,870.40
1,803.00
2,144.40
3,262.60
PBT
7,679.50
7,201.00
6,048.50
3,061.40
2,883.50
1,885.70
2,335.80
1,350.40
1,553.70
2,858.80
Adjustment
1,961.50
1,365.20
1,695.90
2,333.80
2,087.20
2,562.50
835.00
1,625.30
1,687.30
1,107.70
Changes in Working Capital
-2,998.90
-2,018.20
-785.50
-1,840.70
-828.80
-753.60
183.70
-896.60
-519.60
-2.50
Cash after chg. in Working capital
6,642.10
6,548.00
6,958.90
3,554.50
4,141.90
3,694.60
3,354.50
2,079.10
2,721.40
3,964.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,999.30
-2,004.70
-1,071.40
-743.70
-571.60
-710.50
-484.10
-276.10
-577.00
-701.40
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,807.70
-4,028.30
-4,137.30
-2,638.70
-2,266.00
-492.30
-772.70
-1,488.30
-1,840.40
-2,039.40
Net Fixed Assets
-2,403.40
-1,447.20
-1,511.60
-1,303.60
-2,618.10
-453.50
-275.60
-683.20
-1,019.30
-1,892.20
Net Investments
-5,872.90
119.40
-2,503.30
-287.50
836.30
-1,552.00
-297.00
-534.60
1,974.20
-1,213.80
Others
2,468.60
-2,700.50
-122.40
-1,047.60
-484.20
1,513.20
-200.10
-270.50
-2,795.30
1,066.60
Cash from Financing Activity
1,891.10
-376.30
-2,686.10
-242.20
-29.80
-2,515.90
-2,132.60
-444.00
-369.20
-1,700.10
Net Cash Inflow / Outflow
726.20
138.70
-935.90
-70.10
1,274.50
-24.10
-34.90
-129.30
-65.20
-476.90
Opening Cash & Equivalents
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
539.50
Closing Cash & Equivalent
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
400.54
337.21
277.80
1145.98
1052.59
932.31
840.01
752.35
734.72
731.49
ROA
13.41%
16.08%
15.01%
8.08%
8.01%
8.95%
8.66%
4.23%
6.14%
11.05%
ROE
18.61%
21.76%
21.36%
11.93%
11.53%
13.38%
14.42%
7.40%
10.20%
18.95%
ROCE
23.25%
26.86%
26.22%
14.59%
15.24%
10.81%
13.41%
8.21%
9.77%
19.55%
Fixed Asset Turnover
1.13
1.12
1.01
0.96
0.92
0.94
0.87
0.86
0.92
1.13
Receivable days
95.44
99.54
103.01
98.60
95.74
93.92
94.98
100.33
101.86
96.43
Inventory Days
75.27
73.12
73.65
81.57
77.11
71.52
74.03
73.63
69.56
60.11
Payable days
96.23
108.56
108.07
99.98
100.14
39.56
39.46
37.10
31.00
28.67
Cash Conversion Cycle
74.48
64.10
68.59
80.19
72.70
125.88
129.55
136.86
140.42
127.87
Total Debt/Equity
0.14
0.07
0.06
0.18
0.17
0.14
0.28
0.41
0.40
0.27
Interest Cover
28.15
43.09
43.36
32.96
30.23
19.61
26.78
18.14
25.51
35.61

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Dr. Reddy's acquires specialty brands Progynova, Cyclo-Progynova in India
    19th Feb 2026, 10:22 AM

    The acquisition strengthens Dr. Reddy’s gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment

    Read More
  • Dr. Reddy's Laboratories reports 14% fall in Q3 consolidated net profit
    22nd Jan 2026, 10:12 AM

    Consolidated total income increased by 5.75% at Rs 9,022.20 crore for Q3FY26

    Read More
  • Dr. Reddy's Lab - Quarterly Results
    22nd Jan 2026, 00:00 AM

    Read More
  • Dr. Reddy's Laboratories launches Olopatadine Hydrochloride Ophthalmic Solution
    16th Jan 2026, 09:50 AM

    The company’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle

    Read More
  • Dr. Reddy's gets 5 observations from USFDA for Srikakulam formulations facility
    15th Dec 2025, 12:26 PM

    The USFDA conducted a GMP and a Pre-Approval Inspection (PAI) of the said facility

    Read More
  • Dr. Reddy's Laboratories’ arm partners with Immutep’s wholly-owned subsidiary
    8th Dec 2025, 15:58 PM

    Dr. Reddy’s Laboratories SA has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS

    Read More
  • Dr. Reddy’s Laboratories gets European Commission approval for AVT03
    24th Nov 2025, 17:10 PM

    In May 2024, Dr. Reddy’s Laboratories and Alvotech entered into a license and supply agreement for the commercialization of AVT03

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.